Tuesday Nov 26
Ventrus Bio Poised For Run-Up Into Second Round Of Phase III Results
Ventrus Biosciences is focused on the development of treatments for gastrointestinal disorders with a lead product candidate that is currently being evaluated in the second of two planned pivotal Phase III clinical trials.
Ventrus Biosciences Completes Enrollment of Second Pivotal Phase 3...
Ventrus Biosciences, Inc. announced that it has completed patient enrollment and randomization in the second Phase 3 clinical trial of Diltiazem Hydrochloride 2% Cream in patients with pain related to anal fissure .
Shares Of Ventrus Biosciences Are Poised To Return To $12
The new drug application is expected to be submitted in Q2 2014 and because diltiazem is approved for other treatments it should shorten the approval time period.
Ventrus Biosciences Announces Positive Results From Clinical Dermal...
Ventrus Biosciences, Inc. , a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced positive results from two clinical dermal safety studies and one pharmacokinetic study of diltiazem hydrochloride 2% cream .